Saturday 17 October 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.02
0.01
−0.97%
Follow COCP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
10.89 | 7.83 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(5.75) | (5.95) | — | — | |
P/B ratio |
13.87 | 3.38 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
9.21 | 5.16 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(1.54) | (1.21) | — | — | |
EV/FCF |
(1.54) | (1.21) | — | — | |
Quick Ratio |
1.14 | 2.48 | 3.53 | 5.47 | |
Current Ratio |
1.24 | 2.66 | 3.68 | 5.78 | |
Net Debt/EBITDA |
0.75 | 2.03 | 2.97 | 3.90 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | 0.20 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 1.02 | 0.72 | 0.66 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.13) | |
Research and Development Expense of Revenue |
2,040.00% | 609.33% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,092.38% | 537.78% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
87.62% | 37.33% | 0.00% | 0.00% | |
Graham Net Nets |
(0.03) | 0.19 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(72.38%) | (72.28%) | — | — | |
Free Cash Flow Yield |
(55.02%) | (54.62%) | — | — | |
Revenue per Share |
0.01 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.17) | (0.15) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.17) | (0.15) | (0.12) | |
Cash per Share |
0.16 | 0.35 | 0.63 | 0.71 | |
Shareholders Equity per Share |
0.08 | 0.30 | 0.56 | 0.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.08 | 0.30 | 0.56 | 0.70 | |
Free Cash Flow |
(2.52) | (2.34) | (1.74) | (1.37) | |
Working Capital |
0.62 | 3.71 | 5.92 | 7.26 | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
(0.37) | 2.63 | 4.75 | 6.01 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
1.19 | 1.10 | 0.96 | 0.58 | |
Average Payables |
1.89 | 1.75 | 2.00 | 1.42 | |
Average Assets |
6.58 | 9.04 | 11.58 | 13.34 | |
Average Common Equity |
3.19 | 5.71 | 7.93 | 10.19 |
Columns are period end dates